- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Healthy potentially undervalued
U.S. Pharmaceuticals & Biotech Healthy potentially undervalued
Results
87
Companies which are potentially undervalued and in an acceptable financial position.
87 companies
Alkermes
Market Cap: US$5.0b
A biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
ALKS
US$31.07
7D
-1.2%
1Y
6.1%
Myriad Genetics
Market Cap: US$602.2m
A molecular diagnostic testing and precision medicine company, develops and provides molecular tests.
MYGN
US$6.58
7D
-16.8%
1Y
-62.5%
Perrigo
Market Cap: US$2.8b
Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
PRGO
US$15.10
7D
-29.0%
1Y
-44.7%
Charles River Laboratories International
Market Cap: US$8.8b
Charles River Laboratories International, Inc.
CRL
US$167.70
7D
-6.9%
1Y
-21.7%
ADMA Biologics
Market Cap: US$3.5b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$15.37
7D
-1.0%
1Y
-21.9%
Soleno Therapeutics
Market Cap: US$3.4b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$46.97
7D
-32.9%
1Y
-17.4%
Arcus Biosciences
Market Cap: US$2.1b
A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
RCUS
US$19.75
7D
-2.7%
1Y
25.6%
Axsome Therapeutics
Market Cap: US$6.8b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$135.69
7D
1.8%
1Y
49.2%
Niagen Bioscience
Market Cap: US$556.6m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$6.88
7D
-5.4%
1Y
-1.6%
LENZ Therapeutics
Market Cap: US$751.0m
Operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
LENZ
US$21.47
7D
-29.9%
1Y
-33.4%
Avantor
Market Cap: US$7.9b
Engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
AVTR
US$11.58
7D
0%
1Y
-49.6%
Revolution Medicines
Market Cap: US$10.9b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$59.34
7D
2.3%
1Y
-0.1%
Travere Therapeutics
Market Cap: US$3.1b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$33.72
7D
12.5%
1Y
94.9%
Madrigal Pharmaceuticals
Market Cap: US$9.9b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$475.56
7D
12.8%
1Y
40.6%
ACADIA Pharmaceuticals
Market Cap: US$3.7b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$22.33
7D
-0.9%
1Y
41.4%
Illumina
Market Cap: US$17.9b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$122.44
7D
28.8%
1Y
-19.4%
Qiagen
Market Cap: US$9.6b
Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.
QGEN
US$44.05
7D
-6.7%
1Y
-2.4%
Exelixis
Market Cap: US$10.2b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$40.37
7D
2.4%
1Y
13.7%
Adagene
Market Cap: US$80.1m
A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.
ADAG
US$1.50
7D
-18.5%
1Y
-50.7%
ArriVent BioPharma
Market Cap: US$759.0m
A clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
AVBP
US$18.33
7D
-1.9%
1Y
-47.5%
Johnson & Johnson
Market Cap: US$450.2b
Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
JNJ
US$186.00
7D
-0.3%
1Y
17.8%
Caris Life Sciences
Market Cap: US$8.8b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$29.21
7D
-0.7%
1Y
n/a
aTyr Pharma
Market Cap: US$81.0m
A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
ATYR
US$0.81
7D
-16.0%
1Y
-75.0%
Incyte
Market Cap: US$20.2b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$105.70
7D
17.2%
1Y
30.6%
Immunocore Holdings
Market Cap: US$1.6b
A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
IMCR
US$30.80
7D
-6.2%
1Y
-8.1%
Compugen
Market Cap: US$150.6m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$1.64
7D
-0.6%
1Y
-4.7%
Bristol-Myers Squibb
Market Cap: US$92.8b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMY
US$46.47
7D
9.1%
1Y
-15.9%
NovaBridge Biosciences
Market Cap: US$492.2m
A biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.
NBP
US$4.26
7D
-8.0%
1Y
290.8%
Arrowhead Pharmaceuticals
Market Cap: US$5.2b
Develops medicines for the treatment of intractable diseases in the United States.
ARWR
US$40.31
7D
0.05%
1Y
88.9%
Azenta
Market Cap: US$1.4b
Provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.
AZTA
US$30.54
7D
2.5%
1Y
-34.4%
Cabaletta Bio
Market Cap: US$247.0m
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
CABA
US$2.60
7D
4.0%
1Y
-44.1%
enGene Holdings
Market Cap: US$334.3m
Through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer.
ENGN
US$6.34
7D
-13.5%
1Y
-27.7%
Vertex Pharmaceuticals
Market Cap: US$107.0b
A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
VRTX
US$417.00
7D
-0.05%
1Y
-15.5%
Zoetis
Market Cap: US$54.8b
Engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally.
ZTS
US$120.49
7D
-16.3%
1Y
-29.3%
Revvity
Market Cap: US$10.4b
Provides health sciences solutions, technologies, and services.
RVTY
US$92.57
7D
-2.9%
1Y
-25.9%
Cybin
Market Cap: US$155.5m
A clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
CYBN
US$5.95
7D
-20.5%
1Y
-40.1%